Tigermed
Major Chinese CROs and consulting groups (like Tigermed) specialize in bridging the gap between China's National Medical Products Administration (NMPA) and the US FDA for cross-border drug development.
- Country
- China
- Ticker
- SZSE:300347
Commercial
NMPA Focus
Coverage
| CN | EU | IN | US | |
|---|---|---|---|---|
| market-access-commercial | ✓ | ✓ | — | ✓ |
| regulatory-legal | ✓ | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| CMC regulatory consulting (BLA/MAA) | regulatory-legal | Low | → |
| Named-patient programs & compassionate use | market-access-commercial | Low | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.